| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L04 - Immunosuppressants | Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
|
|
| L04A - Immunosuppressants | This group comprises immunosuppressants excl. corticosteroids.
| The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.
|
|
| L04AX - Other Immunosuppressants | Oral formulations and prefilled syringe/pen of methotrexate are classified in this group. Parenteral formulations used for neoplastic diseases are classified in L01BA01.
Dimethyl fumarate indicated for multiple sclerosis or plaque psoriasis is classified here.
| The DDD for thalidomide is based on the treatment of lepra.
The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.
The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.
The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.
|
|
| L04AX03 - Methotrexate | | Dose | Route of administration | Note |
|---|
| | P | | | | O | |
|
|
